M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets BioSpaceAll told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) BioSpace All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. Oncology Read full story Post navigation Previous: Alnylam hops on AI train with up to $2B Inceptive partnershipNext: Peptide biotech Parabilis targets up to $476M IPO Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026